Abstract:PurposeAccurate staging of ovarian cancer is critical to guide optimal management pathways. North American guidelines recommend contrast-enhanced CT as the primary work-up for staging ovarian cancer. This meta-analysis aims to compare the diagnostic accuracy of contrast-enhanced CT alone to PET/CT for detecting abdominal metastases in patients with a new or suspected diagnosis of ovarian cancer.Materials and methodsA systematic review of MEDLINE, EMBASE, Scopus, the Cochrane Library, and the gray literature from inception to October 2022 was performed. Studies with a minimum of 5 patients evaluating the diagnostic accuracy of contrast-enhanced CT and/or PET/CT for detecting stage 3 ovarian cancer as defined by a surgical/histopathological reference standard ± clinical follow-up were included. Study, clinical, imaging, and accuracy data for eligible studies were independently acquired by two reviewers. Primary meta-analysis was performed in studies reporting accuracy on a per-patient basis using a bivariate mixed-effects regression model. Risk of bias was evaluated using QUADAS-2.ResultsFrom 3701 citations, 15 studies (918 patients with mean age ranging from 51 to 65 years) were included in the systematic review. Twelve studies evaluated contrast-enhanced CT (6 using a per-patient assessment and 6 using a per-region assessment) and 11 studies evaluated PET/CT (7 using a per-patient assessment and 4 using a per-region assessment). All but one reporting study used consensus reading. Respective sensitivity and specificity values on a per-patient basis were 82% (67–91%, 95% CI) and 72% (59–82%) for contrast-enhanced CT and 87% (75–94%) and 90% (82–95%) for PET/CT. There was no significant difference in sensitivities between modalities (p = 0.29), but PET/CT was significantly more specific than CT (p < 0.01). Presumed variability could not be assessed in any single category due to limited studies using per-patient assessment. Studies were almost entirely low risk for bias and applicability concerns using QUADAS-2.ConclusionContrast-enhanced CT demonstrates non-inferior sensitivity compared to PET/CT, although PET/CT may still serve as an alternative and/or supplement to CT alone prior to and/or in lieu of diagnostic laparoscopy in patients with ovarian cancer. Future revisions to existing guidelines should consider these results to further refine the individualized pretherapeutic diagnostic pathway.

CT Diagnosis of Ovarian Metastatic Tumors

Application of CT Scan in Diagnosis of Pathological Type and Origin of Metastatic Ovarian Tumors

CT Disgnsis of Metastatic Ovarian Cancer

CT diagnosis of ovarian neoplasm

CT Diagnosis of Serous Ovarian Neoplasm

CT Diagnosis and Differential Diagnosis of Ovarian Cystadenoma and Ovarian Cystadenocarcinoma

Differentiating primary from metastatic ovarian tumors of gastrointestinal origin by CT

Analysis of CT characteristics of peripheral hepatic metastasis from ovarian cancer

CT diagnosis of primary malignant solid cystic ovarian neoplasm

MSCT Anatomy of ovary and its Clinical Value

Secondary ovarian adenocarcinoma:CT and MR imaging features and their diagnostic value

CT Signs Compare with Pathological Diagnosis on Ovarian Cystadenoma and Cystadenoearcinoma

MRI diagnosis of malignant ovarian tumors

CT findings of epithelial origin ovarian carcinoma

Extra-Abdominal Metastases from Epithelial Ovarian Carcinoma an Analysis of 20 Cases

Value of CT manifestations in diagnosis of ovarial cystadenoma and cystadenocarcinoma

Ovarian Cancer Staging-How CT Scan Descriptions Differ from Surgical Findings

Systematic review and meta-analysis of imaging differential diagnosis of benign and malignant ovarian tumors

Diagnostic accuracy of contrast-enhanced CT versus PET/CT for advanced ovarian cancer staging: a comparative systematic review and meta-analysis

Comparative Analysis of Imaging Appearances and Pathological Characteristics in the Group of the Ovarian Thecoma-Fibroma

Spiral CT in the Monitoring of Treated Ovarian Cancer